Researchers at the University of Pennsylvania used AI language models to analyze roughly 150,000 posts and comments from about 40,000 Reddit users describing their experience with retatrutide, an experimental GLP-1 drug that has not been approved by the FDA but is widely available through gray-market compounding pharmacies and overseas suppliers. The study, published in JAMA Network, is described as the first systematic look at the symptoms people attribute to these unapproved products, offering a rare data-driven window into a drug being used by thousands of people outside any clinical trial oversight.
What Retatrutide Is, and Why It’s Not Approved
Retatrutide is a triple-hormone-receptor agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously, a combination early trial data suggested could produce greater weight loss than approved drugs like semaglutide or tirzepatide. Because it remains in Lilly’s clinical trial pipeline and has not cleared FDA review, it is illegal to sell as a finished drug product in the US. Despite that, compounding pharmacies and online sellers have marketed it as a research chemical, creating a gray market that researchers say has ballooned alongside demand for GLP-1 drugs broadly.
How the AI Analysis Worked
The Penn team trained AI models to parse Reddit posts and comments for mentions of specific symptoms, filtering out noise and extracting patterns that would be nearly impossible to identify through manual review of that volume of text. Applying natural language processing at this scale let researchers quantify the frequency of reported side effects and surface which symptoms clustered together in ways unapproved-drug users described, rather than relying solely on self-selected case reports or adverse event filings that are far less complete for gray-market products.
What the Reddit Data Showed
The analysis found users reporting a broad range of symptoms, including gastrointestinal distress, fatigue, and mood changes, consistent with known GLP-1 drug effects, but also surfaced patterns specific to retatrutide’s triple-receptor mechanism that have not been as thoroughly documented in Lilly’s published trial data. Because retatrutide users are self-dosing products of inconsistent purity and concentration from compounding sources, researchers say some reported effects may reflect contamination or dosing errors rather than the drug itself, a distinction that is impossible to resolve from social media text alone.
A Companion Study on Approved Drugs
The same Penn group previously analyzed more than 400,000 Reddit posts about approved GLP-1 drugs semaglutide and tirzepatide, published earlier in 2026, and found users reporting side effects such as menstrual changes and temperature sensitivity that were not fully captured in the drugs’ original clinical trials. Researchers were careful to note those findings establish correlation, not causation, since Reddit users are not a representative or controlled population, but the pattern suggested social media analysis can flag signals worth formal follow-up study.
The Regulatory and Safety Stakes
Doctors and the FDA have repeatedly warned that compounded and gray-market GLP-1 products carry risks that approved drugs do not, including inconsistent dosing, unknown contaminants, and the absence of any pharmacovigilance system to catch dangerous patterns early. Unlike approved drugs, which generate structured adverse event reports the FDA can analyze, gray-market retatrutide users typically have no formal channel to report problems, leaving platforms like Reddit as one of the only places where collective patterns in real-world use become visible at all.
What’s Next
Retatrutide remains in Lilly’s Phase III trial program, and if its full dataset supports approval, it would give patients currently buying unregulated versions a path to a tested, dosage-controlled product instead. In the meantime, researchers say AI-driven social media surveillance could become a template for monitoring other unapproved or gray-market drugs where formal surveillance systems don’t reach, though they caution the method should complement, not replace, controlled clinical data as the basis for safety conclusions.
Photo: Myriams-Fotos / PIXABAY via Pixabay
